Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids.

Shin-Ya TamechikaShin-Ichiro OhmuraShinji MaedaTaio Naniwa

Published in: Journal of bone and mineral metabolism (2022)

Switching to denosumab demonstrated greater efficacy than continuing bisphosphonates in increasing BMD, inhibiting osteoclast activation, and enhancing patient satisfaction in Japanese bisphosphonate-treated osteoporosis and osteopenia patients with concomitant SRD receiving glucocorticoids.

Keyphrases

bone mineral density
patient satisfaction
postmenopausal women
body composition
rheumatoid arthritis
giant cell
signaling pathway
bone loss